ROYALTY PHARMA ANNOUNCES PRICING OF

ROYALTY PHARMA

About Royalty Pharma

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top

Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty

portfolio includes royalties on more than 45 commercial products, including AbbVie and

deko and Trikafta, and

three development-stage product candidates.

Forward-Looking Statements

that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Com

objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of our strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking

negative of these terms or similar expressions.

Forwardassumptions and on information currently available to the Company. However, these
forward-looking statements are not a guarantee of our performance, and you should
not place undue reliance on such statements. Forward-looking statements are subject
to many risks, uncertainties and other variable circumstances, and other factors. Such
risks and uncertainties may cause the statements to be inaccurate and readers are
cautioned not to place undue reliance on such statements. Many of these risks are

cause its actual results to differ materially

from those it thought would occur. The forwardlooking statements included in this document are made only as of the date hereof. The Company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.